Featuring perspectives from Dr Philipp Harter, Dr David M O'Malley and Dr Shannon N Westin, including the following topics:

Up-Front Treatment for Advanced Ovarian Cancer (OC)
- Introduction (0:00)
- Front-line maintenance therapy for patients with advanced OC (3:11)
- Adverse events associated with PARP inhibitors and implications for therapeutic selection (14:17)
- Other considerations for patients with advanced ovarian cancer and germline BRCA mutations: Management of the breast, role of genetic counseling, et cetera (31:03)
The Evolving Management Paradigm for Relapsed/Refractory OC
- PARP inhibitors as later-line therapy for advanced OC (35:20)
- Use of mirvetuximab soravtansine in advanced OC (44:04)
Novel Agents and Strategies Under Investigation for Advanced OC
- Upifitamab rilsodotin in advanced OC (50:10)
- Tumor treating fields in advanced OC (56:03)

Robert McGrath

The AI-powered Podcast Player